[Medullary thyroid carcinoma].
Medullary thyroid carcinoma (MTC) is developed from thyroid C cells that secrete calcitonin (CT). MTC represents 5-10% of thyroid cancers with a 1-2% incidence in nodular thyroid diseases. Diagnosis is usually made by a solitary nodule often associated to nodal metastasis and confirmed by a high basal CT level which represents its biological marker. MTC may present as a sporadic form and in about 30% of case as a familial form as a part of multiple endocrine neoplasia syndrome, an hereditary dominant inherited disease related to germline mutation of the proto-oncogene RET. Both biological (CT) and genetic (RET) markers allows the optimal diagnosis and treatment of MTC; the former allows screening and early diagnosis of MTC by routinely CT measurements in nodular thyroid diseases that make the adequate and complete surgery required to be performed. The former leads to diagnose familial MTC and to identify at risk subjects in whom early or prophylactic surgery may be performed. Treatment of MTC is based on the complete surgical resection: total thyroidectomy associated to central and laterocervical nodal dissection. For locally advanced or metastatic MTC, complete cervical surgery is required and needs to be associated to other systemic treatments: as chemotherapy is not very efficient, radioimmunotherapy and RET target gene therapy (mainly tyrosine kinase inhibitors) appears as possible valuable therapeutic options for the future. Prognosis of MTC is mainly related to both the stage of the disease and the extend of the initial surgery. Ten-year survival is about 80% when the patients are not surgically cured and reaches 95% when the biological marker CT is normalized after surgery.
Niccoli-Sire
P
P
Service d'endocrinologie, diabète et maladies métaboliques, Assistance publique-Hôpitaux de Marseille, faculté de médecine de Marseille, université de la Méditerranée, CHU de La Timone, 13385 Marseille cedex 05, France. patricia.niccoli-sire@ap-hm.fr
Conte-Devolx
B
B
D003937:Diagnosis, Differential; D005602:France; D006801:Humans; D015994:Incidence; D011379:Prognosis; D000090063:Proto-Oncogene Mas; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000235:genetics / Q000601:surgery; D013965:Thyroidectomy